Flavopiridol increases sensitization to gemcitabine in human gastrointestinal cancer cell lines and correlates with down-regulation of ribonucleotide reductase M2 subunit

Clinical Cancer Research

Volumn 7, Issue 8, 2001, Pages 2527-2536

  Jung, Christoph P ^a   Motwani, Monica V ^a   Schwartz, Gary K ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOCHROME C; DNA; FLAVOPIRIDOL; GEMCITABINE; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; RETINOBLASTOMA PROTEIN; RIBONUCLEOTIDE REDUCTASE;

APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CANCER SURVIVAL; COLON CANCER; COLONY FORMATION; CONCENTRATION RESPONSE; DIGESTIVE SYSTEM CANCER; DNA SYNTHESIS; ENZYME REGULATION; ENZYME SUBUNIT; HUMAN; HUMAN CELL; PANCREAS CANCER; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; STOMACH CANCER; TRANSCRIPTION INITIATION;

ANTINEOPLASTIC AGENTS; APOPTOSIS; BLOTTING, WESTERN; CELL CYCLE PROTEINS; CYCLIN D1; CYCLIN E; CYSTEINE ENDOPEPTIDASES; CYTOCHROME C GROUP; DEOXYCYTIDINE; DNA-BINDING PROTEINS; DOSE-RESPONSE RELATIONSHIP, DRUG; DOWN-REGULATION; DRUG SYNERGISM; E2F TRANSCRIPTION FACTORS; E2F1 TRANSCRIPTION FACTOR; ENZYME INHIBITORS; FLAVONOIDS; GASTROINTESTINAL NEOPLASMS; GENE EXPRESSION REGULATION, ENZYMOLOGIC; HUMANS; MITOCHONDRIA; MULTIENZYME COMPLEXES; PHOSPHORYLATION; PIPERIDINES; POLY(ADP-RIBOSE) POLYMERASES; PROTEASOME ENDOPEPTIDASE COMPLEX; PROTEIN SUBUNITS; RETINOBLASTOMA PROTEIN; RIBONUCLEOTIDE REDUCTASES; RNA, MESSENGER; THYMIDINE; TRANSCRIPTION FACTORS; TRITIUM; TUMOR CELLS, CULTURED; TUMOR STEM CELL ASSAY;

EID: 0034887130     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (36)

1. Efficacy and safety profile of gemcitabine in non-small-cell lung cancer: A Phase II study
2. A Phase II study of gemcitabine (LY 188011) in patients with advanced squamous cell carcinoma of the head and neck
3. Evaluation of the antitumor activity of gemcitabine (2′, 2′-difluoro-2′-deoxycytidine)
4. Phase II study of gancitabine as a first-line chemotherapy in patients with advanced or metastatic breast cancer
5. Gemcitabine in the treatment of ovarian cancer
6. Gemcitabine: Metabolism, mechanism of action, and self-potentiation
7. Comparison of the cellular pharmacokinetics and toxicity of 2, 2-difluorodeoxycyctidine and 1-β-D-arabinofuranosylcytosine
8. Regulation of ribonucleotide reductase activity in mammalian cells
9. Isolation and characterization of expressible cDNA clones encoding the M1 and M2 subunits of mouse ribonucleotide reductase
10. Overexpression of transfected human ribonucleotide reductase M2 subunit in human cancer cells enhances their invasive potential
11. Ribonucleotide reductase R2 component is a novel malignancy determination that cooperates with activated oncogenes to determine transformation and malignant potential
12. Overexpression of ribonucleotide reductase as a mechanism of resistance to 2, 2-difluorodeoxycyctidine in the human KB cancer cell line
13. A Phase II trial of gemcitabine in patients with 5-FU-refractory pancreas cancer
14. Assessing clinical benefit in the treatment of pancreas cancer: Gemcitabine compared to 5-fluorouracil
15. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: A randomized trial
16. Phase II trial of gemcitabine in patients with advanced gastric cancer
17. Gemcitabine in patients with advanced malignant melanoma or gastric cancer: Phase II studies of the EORTC Early Clinical Trials Group
18. Phase II study of gemcitabine in advanced colorectal adenocarcinoma
19. Phase II trial of 150-minute weekly infusion of gemcitabine in advanced colorectal cancer: Minimal activity in colorectal cancer
20. Growth inhibition with reversible cell cycle arrest of carcinoma cells by flavone L86-8275
21. Phase I trial of continuous infusion flavopiridol, a novel cyclin-dependent kinase inhibitor, in patients with refractory neoplasms
22. Flavopiridol induces apoptosis in chronic lymphocytic leukemia cells via activation of caspase-3 without evidence of bcl-2 modulation or dependence on functional p53
23. Potent inhibition of CDC2 kinase activity by the flavonoid L86-8275
24. 1 arrest with inhibition of cyclin-dependent kinase CDK2 and CDK4 in human breast carcinoma cells
25. Flavopiridol. A cytotoxic flavone that induces cell death in noncycling A549 human lung carcinoma cells
26. Potentiation of apoptosis by flavopiridol in mitomycin-C-treated gastric and breast cancer cells
27. Sequential dependent enhancement of caspase activation and apoptosis by flavopiridol on paclitaxel-treated human gastric and breast cancer cells
28. Phase I trial of sequential paclitaxel and the cyclin dependent kinase inhibitor flavopiridol
29. Down-regulation of cyclin D1 by transcriptional repression in MCF-7 human breast carcinoma cells induced by flavopiridol
30. The mutational status of p53 protein in gastric and esophageal adenocarcinoma cell lines predict sensitivity to chemotherapeutic agents
31. Flavopiridol, a cyclin-dependent kinase inhibitor, prevents spindle inhibitor-induced endoreduplication in human cancer cells
32. Altered expression of ribonucleotide reductase and role of M2 gene amplification in hydroxyurea-resistant hamster, mouse, rat, and human cell lines
33. 1/S-regulatory genes
34. A Phase I clinical, plasma, and cellular pharmacology study of gemcitabine
35. Mitochondrial cytochrome c release in apoptosis occurs upstream of DEVD-specific caspase activation and independently of mitochondrial transmembrane depolarization
36. Flavopiridol, a protein kinase inhibitor, down-regulates hypoxic induction of vascular endothelial growth factor expression in human monocytes